for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cadila Healthcare Ltd

CADI.NS

Latest Trade

261.00INR

Change

-3.00(-1.14%)

Volume

863,943

Today's Range

259.00

 - 

264.00

52 Week Range

206.50

 - 

359.75

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
264.00
Open
264.00
Volume
863,943
3M AVG Volume
30.36
Today's High
264.00
Today's Low
259.00
52 Week High
359.75
52 Week Low
206.50
Shares Out (MIL)
1,023.74
Market Cap (MIL)
267,196.80
Forward P/E
18.30
Dividend (Yield %)
1.34

Next Event

Q3 2020 Cadila Healthcare Ltd Earnings Release

Latest Developments

More

Cadila Healthcare Says Inspection By US FDA Of Co's API Manufacturing Facility Located At Dabhasa, Gujarat

Cadila Healthcare Says Zydus Announces Regulatory Filing Of Saroglitazar Magnesium

Cadila Healthcare Says Zydus Announces Second Phase 3 Trial Of Desidustat

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cadila Healthcare Ltd

Cadila Healthcare Limited is an India-based pharmaceutical company. The Company's subsidiaries include Zydus Wellness Limited, Windlas Healthcare Pvt Ltd, Liva Pharmaceuticals Limited, Biochem Pharmaceutical Industries Limited, Zydus Technologies Limited, German Remedies Limited, Dialforhealth India Limited, Dialforhealth Unity Limited and Dialforhealth Greencross Limited, among others.

Industry

Biotechnology & Drugs

Contact Info

Zydue Tower, Satellite Cross Road

+91.79.26868100

http://zyduscadila.com/

Executive Leadership

Pankaj Ramanbhai Patel

Non-Executive Chairman of the Board

Nitin D. Parekh

Chief Financial Officer

Dhaval N. Soni

Company Secretary, Chief Compliance Officer

Sharvil P. Patel

Managing Director, Executive Director

Ganesh N. Nayak

Executive Director

Key Stats

2.22 mean rating - 36 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

97.5K

2018

119.0K

2019

131.7K

2020(E)

139.9K
EPS (INR)

2017

14.820

2018

17.350

2019

18.060

2020(E)

14.260
Price To Earnings (TTM)
19.32
Price To Sales (TTM)
1.89
Price To Book (MRQ)
2.59
Price To Cash Flow (TTM)
13.08
Total Debt To Equity (MRQ)
68.77
LT Debt To Equity (MRQ)
36.64
Return on Investment (TTM)
10.39
Return on Equity (TTM)
6.77

Latest News

Latest News

Kraft Heinz to sell part of India business for about $630 million

Kraft Heinz Co <KHC.O> will sell part of its Indian business, including brands such as malt-based drink Complan and energy drink Glucon-D, for 45.95 billion rupees ($627.18 million), at a time when Indian consumers are demanding healthier, sugar-free alternatives.

UPDATE 2-Kraft Heinz to sell part of India business for about $630 mln

* Deal does not assume any debt (Recasts throughout to add background, deal details)

Kraft Heinz to sell part of Indian businesses to drugmaker Zydus: Bloomberg

Kraft Heinz Co <KHC.O> has agreed to sell a portfolio of its Indian businesses, including children's drink brand Complan, to Indian drugmaker Zydus Wellness Ltd, Bloomberg reported on Tuesday, citing sources.

Kraft Heinz to sell part of Indian businesses to drugmaker Zydus - Bloomberg

Kraft Heinz Co has agreed to sell a portfolio of its Indian businesses, including children's drink brand Complan, to Indian drugmaker Zydus Wellness Ltd, Bloomberg reported https://www.bloomberg.com/news/articles/2018-10-23/kraft-is-said-to-agree-to-sell-package-of-indian-assets-to-zydus...

BRIEF-Cadila Healthcare Gets Exit Price For Sale Of Shares To Bayer (South East Asia)

* CADILA HEALTHCARE - GOT EXIT PRICE FOR SALE OF SHARES TO BAYER (SOUTH EAST ASIA) PTE LTD IN TERMS OF JV AGREEMENT Source text: http://bit.ly/2HNe3Uu Further company coverage:

BRIEF-Cadila Healthcare Says Zydus Received Final Approval From USFDA For Bumetanide Tablets USP

* SAYS ZYDUS RECEIVED FINAL APPROVAL FROM USFDA FOR BUMETANIDE TABLETS USP Source text for Eikon: Further company coverage:

BRIEF-Cadila Healthcare To Sell 12.5 Mln Shares Of JV To Bayer (South East Asia)

* SAYS CO IS SELLING 12.5 MILLION SHARES OF JV TO BAYER (SOUTH EAST ASIA) PTE BY EXECUTING SHARE PURCHASE DEAL Source text - https://reut.rs/2r4g6ft Further company coverage:

BRIEF-Cadila Healthcare Says Zydus Gets U.S. FDA Final Nod For Methylprednisolone Tablets USP, Cinacalcet Hydrochloride Tablets

* SAYS ZYDUS GETS FINAL APPROVAL FROM USFDA FOR METHYLPREDNISOLONE TABLETS USP AND CINACALCET HYDROCHLORIDE TABLETS Source text - http://bit.ly/2Hry5Yw Further company coverage:

BRIEF-Cadila Healthcare Says Zydus Gets Final Approval From U.S. FDA For Diclofenac Sodium Topical Solution

* SAYS ZYDUS GETS FINAL APPROVAL FROM U.S. FDA FOR DICLOFENAC SODIUM TOPICAL SOLUTION

BRIEF-India's Cadila Healthcare Says No Observation Issued For Topical Unit

* SAYS TOPICAL FACILITY SUCCESSFULLY COMPLETES USFDA INSPECTION

BRIEF-Cadila Healthcare Says ‍Zydus Gets U.S. FDA Nod For Metoprolol Succinate Extended-Release Tablets USP​

* SAYS ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR METOPROLOL SUCCINATE EXTENDED-RELEASE TABLETS USP Source text - http://bit.ly/2pEyVGd Further company coverage:

BRIEF-Cadila Healthcare Says Zydus Gets Final Nod From U.S. FDA For Tizanidine Tablets USP

* SAYS ZYDUS RECEIVES FINAL APPROVAL FROM U.S. FDA FOR TIZANIDINE TABLETS USP Source text - http://bit.ly/2p5iSkn Further company coverage:

BRIEF-Cadila Healthcare's ‍Zydus Partners With Medicure To Launch Zypitamag In U.S.​

* UNIT ZYDUS PARTNERS WITH MEDICURE TO LAUNCH ITS NDA PRODUCT, ZYPITAMAG (PITAVASTATIN) IN U.S. Source text - http://bit.ly/2oYA0Yx Further company coverage:

BRIEF-Cadila Healthcare's ‍Zydus Gets Final Nod From U.S. FDA For Sedative Injection​

* UNIT ZYDUS GETS FINAL NOD FROM U.S. FDA FOR DEXMEDETOMIDINE HYDROCHLORIDE INJECTION

BRIEF-Cadila Healthcare's Moraiya Facility Successfully Completes U.S. FDA Inspection

* SAYS CO'S MORAIYA FACILITY SUCCESSFULLY COMPLETES U.S. FDA INSPECTION

BRIEF-India's Cadila Healthcare Dec Qtr Consol Profit Up About 68 Pct

* DEC QUARTER CONSOL NET PROFIT 5.43 BILLION RUPEES VERSUS 3.24 BILLION RUPEES LAST YEAR

BRIEF-Cadila Healthcare's Moraiya Manufacturing Facility Inspected By U.S. FDA

* SAYS MANUFACTURING FACILITY AT MORAIYA BEING INSPECTED BY U.S. FDA Source text - http://bit.ly/2nIoJvB Further company coverage:

BRIEF-Cadila Healthcare Says U.S.FDA Completed Inspection At Co's Dabhasa API Facility​

* SAYS USFDA SUCCESSFULLY COMPLETED INSPECTION AT CO'S DABHASA API FACILITY

BRIEF-Cadila Healthcare's Zydus Gets Final Nod From U.S. FDA For Clomipramine Hydrochloride Capsules

* SAYS ZYDUS GETS FINAL APPROVAL FROM U.S. FDA FOR CLOMIPRAMINE HYDROCHLORIDE CAPSULES USP

BRIEF-Cadila Healthcare Says ‍Zydus Gets U.S.FDA Nod For Drug to Treat Hypertension, Chest Pain

* SAYS ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR NIFEDIPINE EXTENDED-RELEASE TABLETS USP

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up